Sarepta Therapeutics Receives MHRA Approval to Continue Dosing in Phase 3 Study of ELEVIDYS for Duchenne Muscular Dystrophy

Reuters

05-21

<a href="https://laohu8.com/S/SRPT">Sarepta Therapeutics</a> Receives MHRA Approval to Continue Dosing in Phase 3 Study of ELEVIDYS for Duchenne Muscular Dystrophy

Sarepta Therapeutics Inc. announced an update regarding its ongoing regulatory review for ELEVIDYS, a gene therapy for Duchenne muscular dystrophy. The Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom has given the green light for dosing to continue uninterrupted in the ENVISION study, which is a global Phase 3 trial. This study involves both non-ambulatory and older ambulatory individuals with Duchenne and is designed as a randomized, double-blind, placebo-controlled trial. Sarepta, a leader in precision genetic medicine for rare diseases, emphasized the significance of this approval as it continues to advance its treatment for Duchenne muscular dystrophy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250521736806) on May 21, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537938236"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537938236\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537938236?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537938236","market":"us","top_or_hot":-1,"title":"Sarepta Therapeutics Receives MHRA Approval to Continue Dosing in Phase 3 Study of ELEVIDYS for Duchenne Muscular Dystrophy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> Receives MHRA Approval to Continue Dosing in Phase 3 Study of ELEVIDYS for Duchenne Muscular Dystrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sarepta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced an update regarding its ongoing regulatory review for ELEVIDYS, a gene therapy for Duchenne muscular dystrophy. The Medicines &amp; Healthcare products Regulatory Agency (MHRA) in the United Kingdom has given the green light for dosing to continue uninterrupted in the ENVISION study, which is a global Phase 3 trial. This study involves both non-ambulatory and older ambulatory individuals with Duchenne and is designed as a randomized, double-blind, placebo-controlled trial. Sarepta, a leader in precision genetic medicine for rare diseases, emphasized the significance of this approval as it continues to advance its treatment for Duchenne muscular dystrophy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250521736806) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sarepta Therapeutics Receives MHRA Approval to Continue Dosing in Phase 3 Study of ELEVIDYS for Duchenne Muscular Dystrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSarepta Therapeutics Receives MHRA Approval to Continue Dosing in Phase 3 Study of ELEVIDYS for Duchenne Muscular Dystrophy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-21 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> Receives MHRA Approval to Continue Dosing in Phase 3 Study of ELEVIDYS for Duchenne Muscular Dystrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sarepta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced an update regarding its ongoing regulatory review for ELEVIDYS, a gene therapy for Duchenne muscular dystrophy. The Medicines &amp; Healthcare products Regulatory Agency (MHRA) in the United Kingdom has given the green light for dosing to continue uninterrupted in the ENVISION study, which is a global Phase 3 trial. This study involves both non-ambulatory and older ambulatory individuals with Duchenne and is designed as a randomized, double-blind, placebo-controlled trial. Sarepta, a leader in precision genetic medicine for rare diseases, emphasized the significance of this approval as it continues to advance its treatment for Duchenne muscular dystrophy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250521736806) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL43Vp5v:1","article_id":"2537938236","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537938236","pubTimestamp":1747830679,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sarepta Therapeutics Inc. announced an update regarding its ongoing regulatory review for ELEVIDYS, a gene therapy for Duchenne muscular dystrophy. The Medicines & Healthcare products Regulatory Agency  in the United Kingdom has given the green light for dosing to continue uninterrupted in the ENVISION study, which is a global Phase 3 trial. This study involves both non-ambulatory and older ambulatory individuals with Duchenne and is designed as a randomized, double-blind, placebo-controlled trial. Sarepta, a leader in precision genetic medicine for rare diseases, emphasized the significance of this approval as it continues to advance its treatment for Duchenne muscular dystrophy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SRPT":"Sarepta Therapeutics","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4139":"生物科技","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"Sarepta Therapeutics获得MHRA批准继续在ELEVIDYS治疗杜氏肌营养不良症的3期研究中给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":0.9},"content_text":"Sarepta Therapeutics Receives MHRA Approval to Continue Dosing in Phase 3 Study of ELEVIDYS for Duchenne Muscular Dystrophy\n    \n\n        Sarepta Therapeutics Inc. announced an update regarding its ongoing regulatory review for ELEVIDYS, a gene therapy for Duchenne muscular dystrophy. The Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom has given the green light for dosing to continue uninterrupted in the ENVISION study, which is a global Phase 3 trial. This study involves both non-ambulatory and older ambulatory individuals with Duchenne and is designed as a randomized, double-blind, placebo-controlled trial. Sarepta, a leader in precision genetic medicine for rare diseases, emphasized the significance of this approval as it continues to advance its treatment for Duchenne muscular dystrophy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250521736806) on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}